New Therapeutic Options in AML: An Update for Community Clinicians

New Therapeutic Options in AML: An Update for Community Clinicians is organized by Haymarket Media Group.

Released: February 11, 2021
Expires: February 11, 2022

Target Audience:
This program is designed for community-based hematologists/oncologists and community-based oncology nurse practitioners and physician assistants.

Accreditation
American Academy of CME, Inc., designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Academy of CME, Inc., designates this educational activity for 0.75 ANCC contact hours (0.50 pharmacotherapeutic contact hours).

Description:
Have you heard about the latest clinical advances in AML therapy? Recent approvals and emerging therapies, such as epigenetic agents and newer cytotoxics, has transformed the care of patients with newly diagnosed and relapsed/refractory AML. Join Drs Stephen A. Strickland and Eunice S. Wang as they discuss recent science that provides guidance for the care team on the use of newly approved and novel strategies for AML management.

Educational Objectives:
Upon completion of the educational activity, participants should be better able to:
• DESCRIBE the mechanisms of action and rationale for the use of recently approved agents in AML management
• SUMMARIZE the indications and safety/efficacy data of novel approved agents
• USE molecular testing appropriately in the selection of targeted treatments utilizing recently approved agents in AML
• DEVELOP strategies to tailor AML treatment by matching individual patients to optimal novel agent(s)/formulation(s)
• EVALUATE the potential role of minimal residual disease assessment in AML management